Mobile

Open-label, randomized, multicenter, international, parallel exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of sta...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002560-33

Open-label, randomized, multicenter, international, parallel exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of stage II-IIIA PAM 50 defined Luminal breast cancer, in postmenopausal women

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the ability of each treatment strategy to provide RCB 0-I pathological tumor response at surgery (local assessment) in luminal A N+ and luminal B patients subgroup.

Critère d'inclusion

  • Post-menopausal patients with localized, stage II-IIIA, candidate for chemotherapy but not candidate or uncertain for breast conservation, PAM50 (Prosigna™)- defined Luminal A and Node-positive or Luminal B (ER+ and HER2-) operable breast cancer (randomized cohort), or Luminal A N- (non randomized cohort)

Liens